title: Anti-glutamate receptor ɛ2 antibodies in psychiatric patients with anti-thyroid autoantibodies--a prevalence study in Japan.
abstract: Patients with anti-thyroid antibodies (ATAs) present various kinds of psychiatric conditions. When these psychiatric patients with ATAs (PPATs) show responsiveness to immunotherapy, they are frequently diagnosed with a diffuse progressive type of Hashimoto's encephalopathy (HE). Anti-glutamate receptor ɛ2 subunit (GluRɛ2) antibodies have previously been reported in HE patients. However, it is unclear whether there is any relationship between PPATs, including HE patients, and anti-GluRɛ2 antibodies. We investigated anti-GluRɛ2 antibodies in the serum and cerebrospinal fluid (CSF) of 15 PPATs, and we compared the results with those of 11 patients with neuropsychiatric systemic lupus erythematosus (NPSLE), an anti-glutamate receptor antibody-related disease. We then compared the neuropsychiatric symptoms between the PPATs with and without anti-GluRɛ2 antibodies. The prevalence of anti-GluRɛ2 antibodies was significantly higher in the CSF than in the serum of PPATs (41.7% versus 6.7%; p=0.040). The prevalence of anti-GluRɛ2 antibodies was slightly higher in the CSF of PPATs than NPSLE patients. PPAT-GluR(+)s showed a significantly higher prevalence of emotional instability (100% versus 33.3%; p=0.03) and also showed a significantly lower prevalence of delusions (0% versus 100%; p=0.001) and hallucinations (17% versus 83%; p=0.038) than PPAT-GluR(-)s. Our results suggest that anti-GluRɛ2 antibodies may be associated with the neuropsychiatric manifestation of PPATs.
authors.affiliation: Department of Psychiatry, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236-0004, Japan.
authors.forename: Yuhei
authors.initials: Y
authors.lastname: Chiba
authors.forename: Omi
authors.initials: O
authors.lastname: Katsuse
authors.forename: Yukitoshi
authors.initials: Y
authors.lastname: Takahashi
authors.forename: Makoto
authors.initials: M
authors.lastname: Yoneda
authors.forename: Misako
authors.initials: M
authors.lastname: Kunii
authors.forename: Atsushi
authors.initials: A
authors.lastname: Ihata
authors.forename: Atsuhisa
authors.initials: A
authors.lastname: Ueda
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Takeno
authors.forename: Takashi
authors.initials: T
authors.lastname: Togo
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Hirayasu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001323:Autoantibodies / Q000097:blood* / Q000134:cerebrospinal fluid*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007453:Iodide Peroxidase / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000276:immunology; D008297:Male; D001523:Mental Disorders / Q000150:complications / Q000276:immunology*; D008875:Middle Aged; D016194:Receptors, N-Methyl-D-Aspartate / Q000276:immunology*; D013954:Thyroglobulin / Q000276:immunology; D013959:Thyroid Diseases / Q000150:complications / Q000276:immunology; D013961:Thyroid Gland / Q000276:immunology*; D055815:Young Adult
chemical_list: D001323:Autoantibodies; C121001:NR2B NMDA receptor; D016194:Receptors, N-Methyl-D-Aspartate; D013954:Thyroglobulin; D007453:Iodide Peroxidase